ImmunoGen, Inc. (NASDAQ:IMGN) Files An 8-K Entry into a Material Definitive Agreement

ITEM 1.01.ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

On May 26, 2017, ImmunoGen, Inc. (ImmunoGen) and sanofi-aventis
U.S. LLC (Sanofi), as successor-in-interest to Aventis
Pharmaceuticals, Inc., entered into a Fourth Amendment (the
Fourth Amendment) to their Collaboration and License Agreement
dated as of July 30, 2003 (as amended, the Collaboration
Agreement). to the Fourth Amendment, ImmunoGen has granted Sanofi
an exclusive, worldwide, fully paid up, royalty-free, perpetual,
irrevocable license to manufacture, develop and commercialize the
following products: (a) isatuximab (SAR650984), an unconjugated
anti-CD38 antibody; (b) SAR408701, an anti-CEACAM5 antibody drug
conjugate, or ADC; (c) SAR566658, an anti-CA6 ADC; and (d) an
additional ADC directed to an undisclosed target. to the Fourth
Amendment, ImmunoGen has also agreed to forego its option to
engage in certain limited co-promotion rights in the U.S. with
respect to the foregoing products.

In connection with the foregoing amendment to the Collaboration
Agreement, ImmunoGen and Sanofi also amended the exclusive
license to our maytansinoid ADC technology for use with
antibodies that target LAMP1 (the LAMP1 License). to the
amendment to the LAMP1 License, ImmunoGen has granted Sanofi an
exclusive, worldwide, fully paid up, royalty-free, perpetual,
irrevocable license to manufacture, develop and commercialize
ADCs targeting LAMP1, including the clinical candidate SAR428926.

In consideration of the foregoing amendments, Sanofi has agreed
to pay ImmunoGen a paid-up license fee in the amount of $30
million.Except for the foregoing paid-up license fee, ImmunoGen
will not be entitled to receive any future milestone payments or
royalties under the Collaboration Agreement or the LAMP1 License.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d): The following exhibit is being filed herewith:

About ImmunoGen, Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

ImmunoGen, Inc. (NASDAQ:IMGN) Recent Trading Information

ImmunoGen, Inc. (NASDAQ:IMGN) closed its last trading session 00.00 at 4.72 with 2,413,289 shares trading hands.